All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
|372||Poster Presentation||Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the Phase 1 solid tumor trial of AMV564, a novel T-cell engager||Sarina A. Piha-Paul, MD; Alexander N. Starodub, MD; Raghad Karim, MD; Michael Shafique, MD; Gabriel R. Tinoco Suarez, MD; Curtis Ruegg, PhD; Victoria Smith, PhD; Patrick Chun, MD;||In-Progress Clinical Trials||Bispecifics; Clinical study; Clinical trial; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment|
|692||Poster Presentation||AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response||Sterling C. Eckard, PhD; Aurelien Sarde; Li Mei; Curtis Ruegg, PhD; Patrick Chun, MD; Victoria Smith, PhD;||Novel Single-Agent Immunotherapies||Clinical trial; Immune suppression; MDSC; Myeloid cells; Solid tumors; T cell; Targeted therapy|